MERIAL

Sainte-Foy-lès-Lyon, France
Sainte-Foy-lès-Lyon, France

Time filter

Source Type

This report studies Veterinary Drugs in Global Market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering  Zoetis(Pfizer)  MERIAL  Merial  Lilly  Bayer  Boehringer  Novartis  Virbac  Ceva  Vetoquinol Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Veterinary Drugs in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India  Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Veterinary biological drugs  Veterinary preparations  Type III  Split by application, this report focuses on consumption, market share and growth rate of Veterinary Drugs in each application, can be divided into  Poultry  Ruminants  Pigs  Pets  Others Global Veterinary Drugs Market Research Report 2016  1 Veterinary Drugs Market Overview  1.1 Product Overview and Scope of Veterinary Drugs  1.2 Veterinary Drugs Segment by Type  1.2.1 Global Production Market Share of Veterinary Drugs by Type in 2015  1.2.2 Veterinary biological drugs  1.2.3 Veterinary preparations  1.2.4 Type III  1.3 Veterinary Drugs Segment by Application  1.3.1 Veterinary Drugs Consumption Market Share by Application in 2015  1.3.2 Poultry  1.3.3 Ruminants  1.3.4 Pigs  1.3.5 Pets  1.3.6 Others  1.4 Veterinary Drugs Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Veterinary Drugs (2011-2021) 2 Global Veterinary Drugs Market Competition by Manufacturers  2.1 Global Veterinary Drugs Production and Share by Manufacturers (2015 and 2016)  2.2 Global Veterinary Drugs Revenue and Share by Manufacturers (2015 and 2016)  2.3 Global Veterinary Drugs Average Price by Manufacturers (2015 and 2016)  2.4 Manufacturers Veterinary Drugs Manufacturing Base Distribution, Sales Area and Product Type  2.5 Veterinary Drugs Market Competitive Situation and Trends  2.5.1 Veterinary Drugs Market Concentration Rate  2.5.2 Veterinary Drugs Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion 3 Global Veterinary Drugs Production, Revenue (Value) by Region (2011-2016)  3.1 Global Veterinary Drugs Production and Market Share by Region (2011-2016)  3.2 Global Veterinary Drugs Revenue (Value) and Market Share by Region (2011-2016)  3.3 Global Veterinary Drugs Production, Revenue, Price and Gross Margin (2011-2016)  3.4 North America Veterinary Drugs Production, Revenue, Price and Gross Margin (2011-2016)  3.5 Europe Veterinary Drugs Production, Revenue, Price and Gross Margin (2011-2016)  3.6 China Veterinary Drugs Production, Revenue, Price and Gross Margin (2011-2016)  3.7 Japan Veterinary Drugs Production, Revenue, Price and Gross Margin (2011-2016)  3.8 Southeast Asia Veterinary Drugs Production, Revenue, Price and Gross Margin (2011-2016)  3.9 India Veterinary Drugs Production, Revenue, Price and Gross Margin (2011-2016) 4 Global Veterinary Drugs Supply (Production), Consumption, Export, Import by Regions (2011-2016)  4.1 Global Veterinary Drugs Consumption by Regions (2011-2016)  4.2 North America Veterinary Drugs Production, Consumption, Export, Import by Regions (2011-2016)  4.3 Europe Veterinary Drugs Production, Consumption, Export, Import by Regions (2011-2016)  4.4 China Veterinary Drugs Production, Consumption, Export, Import by Regions (2011-2016)  4.5 Japan Veterinary Drugs Production, Consumption, Export, Import by Regions (2011-2016)  4.6 Southeast Asia Veterinary Drugs Production, Consumption, Export, Import by Regions (2011-2016)  4.7 India Veterinary Drugs Production, Consumption, Export, Import by Regions (2011-2016) For more information or any query mail at [email protected]


News Article | December 2, 2016
Site: www.newsmaker.com.au

Revenues generated through sales of animal healthcare products and services are expected to reach $35 billion by the end of 2016, according to a report, "Animal Healthcare Market: Global Industry Analysis and Opportunity Assessment 2015 - 2020" by Future Market Insights (FMI). Growing pet humanisation trend and focus on preventive healthcare are expected to drive demand for animal healthcare products, such as feed additives, pharmaceuticals, and vaccines. FMI’s report has broadly segmented the animal healthcare market into production animal and companion animal. Between these, demand for healthcare products and services is higher from the production animal segment. Production animal healthcare revenues totalled nearly $21.8 billion in 2015 vis-à-vis $11.7 billion of companion animals. The key product categories that account for bulk of the revenues in the animal healthcare market are feed additives, pharmaceuticals, and vaccines. Among these, demand for feed additives is the highest, with global revenues totalling $15.7 billion in 2015. By 2020, feed additives are forecasted to account for nearly 48% revenues of the global animal healthcare market. US, China, and France Among the Largest Markets FMI’s report has analysed the animal healthcare market in North America, Europe, Latin America, Asia Pacific, and Middle East and Africa. North America, Europe, and Asia-Pacific account for nearly 88% revenues of the global market. The US, China, Japan, France, Germany, and the U.K. are among the most lucrative markets for companies operating in the animal healthcare landscape. The North America animal healthcare market was valued at $11.3 billion in 2015, of which the U.S. accounted for nearly $9.2 billion. FMI’s report forecasts the market to increase at 4.5% CAGR through 2020 to reach $14.1 billion in revenues. The Europe animal healthcare market was valued at $9.6 billion in 2015; it is estimated to expand at 4.7% CAGR through 2020 and total $12.2 billion in revenues. France is the largest market for animal healthcare products and services in Europe, accounting for $1.9 billion in revenues in 2015. FMI’s report forecasts Turkey to be the fastest growing country in the Europe animal healthcare market. The Asia Pacific animal healthcare market was valued at $8.3 billion in 2015, and FMI estimates it to expand at 6.2% CAGR through 2020. China is the most lucrative country in the Asia Pacific animal healthcare market, and is expected to expand at the fastest CAGR in Asia Pacific. By 2020, China is expected to represent nearly 62% market share. Some of the leading players operating in the pharmaceutical & vaccine segment of animal healthcare market include Bayer Healthcare AG, Merck & Co., Inc. (Intervet), Virbac S.A, Eli Lilly and Company (Elanco/Novartis), Vetoquinol SA, Zoetis, Inc. (Pfizer), Ceva Santé Animale, Boehringer Ingelheim GmbH, Nutreco N.V. and Sanofi S.A. (MERIAL Limited).


News Article | November 1, 2016
Site: www.newsmaker.com.au

Revenues generated through sales of animal healthcare products and services are expected to reach $35 billion by the end of 2016, according to a report, "Animal Healthcare Market: Global Industry Analysis and Opportunity Assessment 2015 - 2020" by Future Market Insights (FMI). Growing pet humanisation trend and focus on preventive healthcare are expected to drive demand for animal healthcare products, such as feed additives, pharmaceuticals, and vaccines. FMI’s report has broadly segmented the animal healthcare market into production animal and companion animal. Between these, demand for healthcare products and services is higher from the production animal segment. Production animal healthcare revenues totalled nearly $21.8 billion in 2015 vis-à-vis $11.7 billion of companion animals. The key product categories that account for bulk of the revenues in the animal healthcare market are feed additives, pharmaceuticals, and vaccines. Among these, demand for feed additives is the highest, with global revenues totalling $15.7 billion in 2015. By 2020, feed additives are forecasted to account for nearly 48% revenues of the global animal healthcare market. US, China, and France Among the Largest Markets FMI’s report has analysed the animal healthcare market in North America, Europe, Latin America, Asia Pacific, and Middle East and Africa. North America, Europe, and Asia-Pacific account for nearly 88% revenues of the global market. The US, China, Japan, France, Germany, and the U.K. are among the most lucrative markets for companies operating in the animal healthcare landscape. The North America animal healthcare market was valued at $11.3 billion in 2015, of which the U.S. accounted for nearly $9.2 billion. FMI’s report forecasts the market to increase at 4.5% CAGR through 2020 to reach $14.1 billion in revenues. The Europe animal healthcare market was valued at $9.6 billion in 2015; it is estimated to expand at 4.7% CAGR through 2020 and total $12.2 billion in revenues. France is the largest market for animal healthcare products and services in Europe, accounting for $1.9 billion in revenues in 2015. FMI’s report forecasts Turkey to be the fastest growing country in the Europe animal healthcare market. The Asia Pacific animal healthcare market was valued at $8.3 billion in 2015, and FMI estimates it to expand at 6.2% CAGR through 2020. China is the most lucrative country in the Asia Pacific animal healthcare market, and is expected to expand at the fastest CAGR in Asia Pacific. By 2020, China is expected to represent nearly 62% market share. Some of the leading players operating in the pharmaceutical & vaccine segment of animal healthcare market include Bayer Healthcare AG, Merck & Co., Inc. (Intervet), Virbac S.A, Eli Lilly and Company (Elanco/Novartis), Vetoquinol SA, Zoetis, Inc. (Pfizer), Ceva Santé Animale, Boehringer Ingelheim GmbH, Nutreco N.V. and Sanofi S.A. (MERIAL Limited).


News Article | December 2, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Veterinary Healthcare market is accounted for $24.34 billion in 2015 and is expected to reach $40.8 billion by 2022 growing at a CAGR of 7.6% from 2015 to 2022. Factors such as food safety and improved nutrition, increase in pet ownership, increasing awareness of zoonotic diseases and increasing animal population are driving the market. However, increasing cost of animal testing, increased competition for cultivated land restrictions established by regulatory bodies will challenge the veterinary market. Feed additives held the largest share among the products segment followed by pharmaceuticals and vaccines. Europe is the leading market in veterinary healthcare followed by North America. Asia-pacific and other developing regions will be the major contributors to the market. Some of the key players in global Veterinary Healthcare market are Merck & Co., Inc, MERIAL Limited, Zoetis Inc, Novartis Animal Health Inc, Bayer HealthCare, Ceva Santé Animale, Boehringer Ingelheim GmbH, Virbac SA, Elanco Products Company, Vétoquinol SA, Sanofi-Aventis, Intas Pharmaceuticals Ltd., Heska Corporation, PetAg Incorporated and Procter & Gamble Company. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific       • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


Patent
Merial, Queen's University of Belfast and University of Saskatchewan | Date: 2011-09-07

The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.


Beugnet F.,Merial | Chalvet-Monfray K.,Ecole Veterinaire de Lyon
Comparative Immunology, Microbiology and Infectious Diseases | Year: 2013

Vector-borne diseases are medically important in humans and animals but were long considered tropical and known to first affect production animals. This is no longer true and we can see today that they are common in domestic animals and that they are also present in temperate countries, especially in Europe. In recent years, an increase in the diagnosis of vector borne diseases among humans and animals has been observed, which may partly due to the development of diagnostic tools. Their study requires exchanges and collaborations between the many actors involved, especially since the epidemiology seems to be constantly evolving. The veterinary practitioner is the first one to notice the emergence of cases and to implement prevention measures. He also acts as a sentinel to alert epidemiologists. Many factors can explain the epidemiological changes, i.e. all human factors, such as the increase in commercial transportation, but also owners traveling with their pet during the holidays, the development of "outdoor" activities, the increase of individual housings with gardens; to these human factors must be added the ignorance of the risks, linked to animals in general and to wildlife in particular; then the environmental changes: forest fragmentation, establishment of parks; the increase of wild mammal populations (deer, carnivores, rodents, etc.); finally, climate changes. Climate change is a reality which may explain the increase of density of arthropod vectors, but also of their hosts, changes in periods of activity and variations in geographical distribution. The authors show the proof of the climate modifications and then explain how it has an impact in Europe on ticks, mosquitoes, sandflies and even fleas. They conclude on the practical consequences for veterinary practitioners, especially with the diagnosis of parasitic diseases or diseases in areas where they usually do not occur. However, not any epidemiological modification should be linked to climate change, since many other factors are involved and often even overriding. © 2013 The Authors.


Beugnet F.,Merial | Franc M.,Ecole Veterinaire de Toulouse
Trends in Parasitology | Year: 2012

External antiparasitic drugs used in cats and dogs have evolved in terms of active ingredients but also regarding formulations. Old chemical groups have been supplanted by phenylpyrazoles, neonicotinoids, oxadiazines, spinosyns or others which are entering the veterinary market. In addition to insecticides-acaricides, insect and mite growth inhibitors (IGRs) have emerged. These IGRs are used in animals or in the environment, either alone or in combination with insecticides-acaricides. The notion of antiparasitic treatment has evolved to the concept of prevention of ectoparasite infestation but also of transmitted diseases through the introduction of formulations providing long-lasting activity. At the same time, ease-of-use has been improved with the development of spot-on formulations. Progress has also been achieved through the development of antiparasitic drugs providing control of both external and internal parasites. © 2012 Elsevier Ltd.


Trademark
Merial | Date: 2015-11-02

Pharmaceutical preparations, namely, antiparasitic preparations.


Trademark
Merial | Date: 2016-01-19

Soaps, shampoos, lotions, dentifrices, toiletries and cosmetic care products for animals; cotton sticks for cosmetic use for animals; skin care preparations for animals. Sanitary products and preparations for veterinary use; dietetic substances for veterinary use; dressings and plasters for veterinary use; disinfectants for veterinary use; preparations for destroying vermin; parasiticides, fungicides; pharmaceutical products, medicines and vaccines for veterinary use; pharmaceutical products for skin care in animals; cotton sticks for veterinary use; medicinal nutritional supplements for animals. Surgical, medical, dental and veterinary apparatus and instruments, universal ticks hook; artificial limbs, eyes and teeth; Orthopedic articles; Suture materials. Foodstuffs for animals, pet food; dry foodstuffs for animals; dog biscuits; edible chewing bones and sticks for animals; edible treats for animals.


Trademark
Merial | Date: 2016-05-31

Animal care products, namely, soaps, shampoos, skin lotions, hair lotions, dentifrices, and non-medicated toiletries and cosmetics; cotton sticks for cosmetic use for animals; non-medicated skin care preparations for animals.

Loading MERIAL collaborators
Loading MERIAL collaborators